Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Myriad Genetics Inc MYGN
$3.93
▲ +2.08%
(+$0.08)
Open
$3.88
Prev Close
$3.85
Day Range
$3.83 – $3.95
52W Range
$3.53 – $8.59
Market Cap
$371.18M
Beta
1.75
EPS (TTM)
$-4.32
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1995-10-06 |
| Shares Out. | 94,450,000 |
| Website | myriad.com/ ↗ |
| Phone | 13026587581 |
Myriad Genetics Inc is a publicly traded company under the ticker symbol MYGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-05-01)
📰 Latest News for MYGN
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)
3 of Wall Street’s Favorite Stocks with Open Questions
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions